Key findings
- During this reporting period (10 October 2022 to 21 May 2023), 2868 people across Australia participated in the TraX study. Most participants were from New South Wales (83.9%).
- The monthly testing for mpox remained consistently low at around 1.0%.
- At study entry, 22.2% of participants reported being unvaccinated against mpox, 50.1% had received one vaccination, and 27.7% had received two mpox vaccinations.
- As of 21 May 2023, the proportion of people who reported being unvaccinated against mpox had reduced by more than half to 9.5%, leaving 273 participants unvaccinated. The proportion who reported having received only one mpox vaccination also fell to 11.3% and the proportion who had received both mpox vaccinations increased to 79.1%.
- At study entry, 11 participants reported prior mpox infection.
